Kings Path Partners’s Eton Pharmaceutcials ETON Stock Holding History

Kings Path Partners’s Portfolio ETON Stock Details ETON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$181K	Buy	+3,515	New	+$178K	0.05%	125

Other funds holding ETON

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Juncture Wealth Strategies Scottsdale, Arizona $390M AUM 19.15% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Sigma Planning Corp Ann Arbor, Michigan $3.88B AUM 23.38% 1-Year Est. Return

Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

BankChampaign National Association Champaign, Illinois $120M AUM 54.13% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

Quantum Private Wealth Tampa, Florida $391M AUM 50.76% 1-Year Est. Return

Kings Path Partners's ETON Position: Q3 2026 in Review

Kings Path Partners opened a new position in Eton Pharmaceutcials (ETON) in Q3 2026: 3,515 shares worth $181K. The stake represents 0.05% of the portfolio and ranks #125 among its holdings.

31 funds tracked by Wall St. Rank hold ETON as of Q3 2026.

Kings Path Partners held 3,515 shares of Eton Pharmaceutcials worth $181K as of Q3 2026.
Eton Pharmaceutcials was a new Kings Path Partners position in Q3 2026.
Eton Pharmaceutcials made up 0.05% of Kings Path Partners's portfolio in Q3 2026, its #125 holding.
31 funds tracked by Wall St. Rank held Eton Pharmaceutcials as of Q3 2026.

Based on Kings Path Partners's 13F filing for Q3 2026, filed 21 Oct 2026.